anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Widely-spread among women, breast cancer is a malignancy with fatalities, and chemotherapy is a vital treatment option for it. Recent studies have underscored the potential of chemotherapeutic agents such as paclitaxel, adriamycin, cyclophosphamide, and gemcitabine, among others, in facilitating tumor metastasis, with paclitaxel being extensively researched in this context. The molecular mechanism of these genes and their potential relevance to breast cancer is noteworthy.
METHOD: Clinical tissue specimens were used to analyze the expression and clinical significance of FGF19 or P-FGFR4 in patients with breast cancer before and after chemotherapy. qRT-PCR, ELISA, immunofluorescence and Western blotting were used to detect the expression level of FGF19 in breast cancer cells. The biological impacts of paclitaxel, FGF19, and ATF4 on breast cancer cells were assessed through CCK8, Transwell, and Western blot assays. The expression of ATF4 in breast cancer cells was determined through database analysis, Western blot analysis, qRT-PCR, and immunofluorescence. The direct interaction between FGF19 and ATF4 was confirmed by a luciferase assay, and Western blotting was used to assess the levels of key proteins in the stress response pathway. To confirm the effects of PTX and FGF19 in vivo, we established a lung metastasis model in nude mice.
RESULTS: FGF19 expression was increased in breast cancer patients after chemotherapy. Paclitaxel can boost the migration and invasion of breast cancer cells, accompanied by an increase in FGF19 expression. ATF4 might be involved in facilitating the enhancing effect of FGF19 on breast cancer cell migration. Finally, stimulation during paclitaxel treatment could trigger a stress response, influencing the expression of FGF19 and the migration of breast cancer cells.
CONCLUSION: These data suggest that paclitaxel regulates FGF19 expression through ATF4 and thus promotes breast cancer cell migration and invasion.
PURPOSE: A composition containing a material which suppresses Ahnak gene expression is provided to effectively prevent or treat obesity. CONSTITUTION: A composition for preventing or treating obesity contains a material which suppresses Ahnak gene expression. The material is an antisense oligonucleotide, siRNA, or aptamer. The composition additionally contains pharmaceutically acceptable carrier. A food composition for treating obesity contains the composition. A method for screening a therapeutic agent for obesity comprises: a step of treating a subject suspicious for obesity with a candidate material for treating obesity; and a step of comparing mRNA or protein expression level of a control group and Ahnak gene.
PURPOSE:To depress a melting point and a gel point of an aqueous gel of carrageenan or furcellaran without damaging properties such as elasticity, taste, etc. and to save heat and operation time, by adding a specific amount of a sodium phosphate to an aqueous gel of carrageenan or furcellaran, blending them uniformly. CONSTITUTION:An aqueous gel of carrageenan and/or furcellaran is blended uniformly with a sodium phosphate (e.g., sodium hexametaphosphate, sodium pen tapolyphosphate, etc.) in an amount to give <=twice (preferably 2-1/50 times) that of the aqueous gel as an auxiliary to depress a melting point, so that the melting point of the gel is depressed. EFFECT:A melting point of a mixture of the aqueous gel, fruit juice, coffee, etc. is raised higher than the melting point of the natural melting point, but the degree of the rise is suppressed to the minimum. This aqueous gelations substance is easily released from a container and its shape slightly collapses.
PURPOSE:To obtain the subject new compound useful for a cosmetic, showing excellent ultraviolet light absorbing action in a wide wavelength region, having excellent stability, light stability and oil solubility. CONSTITUTION:A compound of formula I (R<1> and R<2> are each a hydrocarbon). The compound is obtained by condensing 2,4,6-tri(4-formylphenoxy)-striazine of formula II with a malonate derivative of formula III in the presence of a catalyst (e.g. piperidine-acetic acid) in a solvent (e.g. benzene). Since the compound of formula I absorbs ultraviolet light in a wide wavelength region from UV-A to UV-B and is hardly decomposed with an amount of sunlight to which human is daily exposed, it hardly has an influence on skin caused by a decomposition product, etc. It has no problem in terms of stability, toxicity, irritation, etc. The compound of formula I has excellent affinity for other cosmetic bases and an ultraviolet light absorber and a cosmetic containing the compound of formula I show an excellent feeling of use and durability of ultraviolet light screening action.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to biotechnology, more specifically to producing a neutralising epitopes for an anti-GdF-8 antibody, and can be used in medicine. Produced are peptide versions of the area of 327 to 346 amino acid of the sequence SEQ ID NO: 1 which is specifically bound with rat's monoclonal antibody 788. Peptides are produced by a recombinant method with using a host cell transformed by an expression vector with nucleic acid coding said peptide version. The produced peptides are used to prepare vaccine compositions which are used to elicit an anti-GdF-8 immune response and to enable GDF-8 activity down-regulation in an animal. Also, the produced peptides can be used in a method of anti- antibodies selection screening. ^ EFFECT: produced peptides exhibit the anti-GdF-8 antibody binding activity thereby applicable for the decreased activity of a growth and differentiation factor 8. ^ 17 cl, 2 dwg, 6 tbl, 5 ex
It was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received incentive spirometer training techniques and traditional program of chest physiotherapy. (Five times per week for two months).
Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
Standard rehabilitation protocol will be administered to the control group. In the standard rehabilitation protocol for the first three days after surgery, 3 sets of exercises will be applied as 10 repetitions. The treatment will be initiated for the patients with tolerable coughing and deep breathing exercises. Active dorsi-plantar flexion of the ankle, isometric contraction for the quadriceps, hamstrings and gluteus maximus, for the knee in the supine position on the bed; active heel shift exercises, straight leg raising and standing knee and hip flexion, active hamstring curling, and self-hamstring stretching will be performed. After the exercise, the morning treatment protocol will be completed with a walker at a tolerable distance. The patient will be given assignment in the form of walking and repetition of morning exercises at a tolerable level at least twice during the day.
The present invention discloses a bittersweet extract, which is the second extract and the third extract containing the bittersweet from the bittersweet of the bittersweet plant. The extract has good treatment effect for a plurality of kinds of tumor after experiment demonstration in pharmacodynamics and toxicology. The extract, has definite effective component, which is beneficial to guarantee the safety and the effectiveness. Extraction rate of the raw material is high and the cost is low. Also the operation is convenient, which is applicable for technical production. Therefore the medicine has wide application prospect.
Gastric cancer (GC) is a highly heterogeneous disease with a complex tumor microenvironment (TME) that encompasses multiple cell types including cancer cells, immune cells, stromal cells, and so on. Cancer-associated cells could remodel the TME and influence the progression of GC and therapeutic response. Single-cell RNA sequencing (scRNA-seq), as an emerging technology, has provided unprecedented insights into the complicated biological composition and characteristics of TME at the molecular, cellular, and immunological resolutions, offering a new idea for GC studies. In this review, we discuss the novel findings from scRNA-seq datasets revealing the origin and evolution of GC, and scRNA-seq is a powerful tool for investigating transcriptional dynamics and intratumor heterogeneity (ITH) in GC. Meanwhile, we demonstrate that the vital immune cells within TME, including T cells, B cells, macrophages, and stromal cells, play an important role in the disease progression. Additionally, we also overview that how scRNA-seq facilitates our understanding about the effects on individualized therapy of GC patients. Spatial transcriptomes (ST) have been designed to determine spatial distribution and capture local intercellular communication networks, enabling a further understanding of the relationship between the spatial background of a particular cell and its functions. In summary, scRNA-seq and other single-cell technologies provide a valuable perspective for molecular and pathological disease characteristics and hold promise for advancing basic research and clinical practice in GC.
Enzymatically converted chicken bile (CB), prepared by converting taurine deoxycholic acid (TCDCA) to taurine ursodeoxycholic acid (TUDCA) in CB, possesses various functional activities. But their nutrient composition and safety assessment have not been fully investigated yet. CB was mainly composed of proteins and steroids. CB did not show genotoxic effects based on Ames test, mammalian erythrocyte micronucleus test, and in vitro mammalian chromosomal aberration test. There were no growth abnormalities or deaths in the acute toxicity test for mice, indicating that CB is nontoxic with an LD50 > 10 g/kg·body weight (BW). Subchronic toxicity test and genotoxicity test were performed based on intake of 0.5 g CB per person daily at expanded doses of 33.3, 100, and 300 times (278, 833, and 2500 mg/kg·BW). The result indicated that CB at 833 mg/kg·BW showed no toxicity on BW, body weight gain, food intake, hematological, serum biochemistry, absolute/relative organ weights, urinalysis, and pathological features of rats in the subchronic toxicity test, while CB at 833 mg/kg·BW induced maternal toxicity with no fetus teratogenicity or embryotoxicity in the teratogenicity test. In conclusion, CB did not show toxic effects and a long-term daily intake of CB at 0.5 g per person is considered safe, but pregnant women should avoid it. These findings could provide a reference for the safe use of CB in functional food.
Hundred and five pediatric patients who scheduled for abdominal surgery in ASA I-II risk groups were enrolled in the study. The patients were randomly separated into three groups. Group M (n=35) applied CD player and Group S (n=35) received the independent anesthesiologist placed earplugs into the patients' ears. Group N (n=35) exposed to the ambient operating room noise. The preoperative children's anxiety levels were assessed with the M-YPAS in the operating room. Heart rate (HR) and mid-arterial pressure (MAP) were recorded at 30-minute intervals until the completion of surgery, end of surgery and postoperative. During each measurement, noise level recordings were performed using sonometre. Pediatric Anesthesia Emergence Delirium Score (PEAD) was assessed after extubation, postoperative.
BACKGROUND: The impact of chronic hepatic infection on antigen non-specific immune cells in circulation remains poorly understood. We reported lasting global hyperfunction of peripheral CD8 T cells in HCV-infected individuals with cirrhosis. Whether gene expression patterns in bulk CD8 T cells are associated with the severity of liver fibrosis in HCV infection is not known.
METHODS: RNA sequencing of blood CD8 T cells from treatment naïve, HCV-infected individuals with minimal (Metavir F0-1 ≤ 7.0 kPa) or advanced fibrosis or cirrhosis (F4 ≥ 12.5 kPa), before and after direct-acting antiviral therapy, was performed. CD8 T cell function was assessed by flow cytometry.
RESULTS: In CD8 T cells from pre-DAA patients with advanced compared to minimal fibrosis, Gene Ontology analysis and Gene Set Enrichment Analysis identified differential gene expression related to cellular function and metabolism, including upregulated Hedgehog (Hh) signaling, IFN-α, -γ, TGF-β response genes, apoptosis, apical surface pathways, phospholipase signaling, phosphatidyl-choline/inositol activity, and second-messenger-mediated signaling. In contrast, genes in pathways associated with nuclear processes, RNA transport, cytoskeletal dynamics, cMyc/E2F regulation, oxidative phosphorylation, and mTOR signaling, were reduced. Hh signaling pathway was the top featured gene set upregulated in cirrhotics, wherein hallmark genes GLI1 and PTCH1 ranked highly. Inhibition of Smo-dependent Hh signaling ablated the expression of IFN-γ and perforin in stimulated CD8 T cells from chronic HCV-infected patients with advanced compared to minimal fibrosis. CD8 T cell gene expression profiles post-DAA remained clustered with pre-DAA profiles and disparately between advanced and minimal fibrosis, suggesting a persistent perturbation of gene expression long after viral clearance.
CONCLUSIONS: This analysis of bulk CD8 T cell gene expression in chronic HCV infection suggests considerable reprogramming of the CD8 T cell pool in the cirrhotic state. Increased Hh signaling in cirrhosis may contribute to generalized CD8 T cell hyperfunction observed in chronic HCV infection. Understanding the lasting nature of immune cell dysfunction may help mitigate remaining clinical challenges after HCV clearance and more generally, improve long term outcomes for individuals with severe liver disease.
BACKGROUND: Ventilator-associated pneumonia (VAP) may be a particular concern in patients with severe coronavirus disease 2019 (COVID-19). We aimed to determine the prevalence and etiology of VAP in critically ill COVID-19 patients in a Danish intensive care unit (ICU) during the first three waves of the COVID-19 pandemic and to study associations between dexamethasone (DXM) use and development of VAP.
METHODS: In an observational single-center study patients were retrospectively screened for VAP including causative pathogens, use of DXM and commonly used antibiotics. Diagnosis of VAP required invasive mechanical ventilation (IMV) >48 h with presence of a new bacterial agent and clinical signs of infection. For analysis, common descriptive statistics were applied. Cox proportional hazards models were used to analyze the association between DXM use and VAP.
RESULTS: VAP was detected in 53/119 (44.5%) mechanically ventilated patients across all three COVID-19 waves. Median length of IMV for VAP patients was 24 [15-41] days, and 3 out of 4 were males. VAP was most prevalent (47.0%) during the second wave. Common pathogens included Klebsiella pneumoniae (24.5%), Enterobacter aerogenes (17.0%) and Pseudomonas aeruginosa (13.2%), Staphylococcus aureus (13.2%), and Escherichia coli (13.2%). A change from Gram-negative bacteria only to a combination of Gram-positive and Gram-negative bacteria was observed in the second wave compared to first. Use of DXM was not associated with VAP (adjusted hazard ratio 1.63 95% CI: 0.84-3.17).
CONCLUSION: The prevalence of VAP was high across all three COVID-19 waves and showed a different distribution of pathogens between the first and second wave. Use of DXM was not associated with VAP development. Further and larger studies are needed to understand the risk factors associated with VAP in patients with COVID-19.
A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
PROBLEM TO BE SOLVED: To provide a medical image data processing terminal device having improved image reading efficiency.SOLUTION: A medical image data processing terminal device includes an acquisition unit, a projection unit, an imaging unit, an extraction unit and a data processing unit. The acquisition unit acquires medical image data. The projection unit projects medical images based on the acquired medical image data. The imaging unit captures an image of the projected medical image and generates image data. The extraction unit extracts a user's operation performed on the projected medical image as a target on the basis of the image data. The data processing unit associates the content of the extracted operation with the medical image data.SELECTED DRAWING: Figure 2
Gastrointestinal (GI) complications are significant manifestations of COVID-19 and are increasingly being recognized. These complications range from severe acute pancreatitis to colitis, adding complexity to diagnosis and management. A comprehensive database search was conducted using several databases. Our inclusion criteria encompassed studies reporting severe and long-term GI complications of COVID-19. Digestive disorders were categorized into infections, inflammatory conditions, vascular disorders, structural abnormalities, other diagnoses, and undiagnosed conditions. Of the 73 studies that were selected for full-text review, only 24 met our inclusion criteria. The study highlights a broad range of gastrointestinal complications following COVID-19 infection (excluding liver complications, which are examined separately), including inflammatory conditions, such as ulcerative colitis (UC), acute pancreatitis, and multisystem inflammatory syndrome in children (MIS-C). Other GI complications were reported such as vascular disorders, including diverse thrombotic events and structural abnormalities, which ranged from bowel perforations to adhesions. Additionally, undiagnosed conditions like nausea and abdominal pain were prevalent across different studies involving 561 patients. The findings emphasize the substantial impact of COVID-19 on the GI tract. Ongoing research and monitoring are crucial to understanding the long-term effects and developing effective management strategies for these complications.
The objectives of this study were to evaluate the influence of environmental effects on growth curve traits of Zandi lambs and estimate their genetic parameters with the best-fit animal model. For this purpose, live body weight (BW) records (n = 10,607) of 2,519 individuals (which were progeny of 278 rams and 1,485 ewes) were used to estimate genetic effects on growth curve traits from birth to yearling age of Zandi lambs. Using the Stochastic Approximation Expectation Maximization (SAEM) algorithm the growth curve parameters of five different mixed functions (i.e., Brody, Richards, Von Bertalanffy, Gompertz and Logistic) were obtained, then for the most appropriate model the genetic parameters were estimated using a Bayesian approach fitted multivariate animal model and ignoring or including maternal genetic effect. Except Richards model, all other mixed functions used here closely fitted actual BW records (R2 > 0.96). However, the Logistic function provided the best fit in every type. So, studied growth curve traits were estimated asymptotic weight which considered as mature weight (a), rate parameter (b), rate of maturing (k), and age (Ai)/weight (Wi) at the point of inflection. Of the fixed effects studied (i.e., gender, birth type, dam age, season and year of birth), the only non-significant relationship was the effect dam age on b and Ai. Based on the best-fitted model, posterior means of heritability estimates for a, b, k, Wi and Ai were 0.142 ± 0.036, 0.094 ± 0.029, 0.143 ± 0.063, 0.149 ± 0.039 and 0.029 ± 0.013, respectively. Posterior means of genetic correlations between mentioned traits ranged from -0.018 ± 0.069 (b-k) to 0.959 ± 0.029 (a-b), whereas the phenotypic correlation varied from -0.047 ± 0.014 (b-k) to 0.836 ± 0.007 (a-b). It was concluded that the model including only direct additive effect was sufficient to explain the variation in all investigated growth traits of Zandi lambs, selection for these traits results in slow genetic gain (due to the lack of sufficient genetic variation), but it would not be difficult to improve their mature weight and rate of maturing jointly. The results indicate that although the rate of genetic change for mature weight has been small (0.008 ± 0.003 kg year-1; P < 0.05) but in the favorable direction for this breed.
Variant annotations are crucial for efficient identification of pathogenic variants. In this study, we retrospectively analyzed the utility of four annotation tools (allele frequency, ClinVar, SpliceAI, and Phenomatcher) in identifying 271 pathogenic single nucleotide and small insertion/deletion variants (SNVs/small indels). Although variant filtering based on allele frequency is essential for narrowing down on candidate variants, we found that 13 de novo pathogenic variants in autosomal dominant or X-linked dominant genes are registered in gnomADv4.0 or 54KJPN, with an allele frequency of less than 0.001%, suggesting that very rare variants in large cohort data can be pathogenic de novo variants. Notably, 38.4% candidate SNVs/small indels are registered in the ClinVar database as pathogenic or likely pathogenic, which highlights the significance of this database. SpliceAI can detect candidate variants affecting RNA splicing, leading to the identification of four variants located 11 to 50 bp away from the exon-intron boundary. Prioritization of candidate genes by proband phenotype using the PhenoMatcher module revealed that approximately 95% of the candidate genes had a maximum PhenoMatch score ≥ 0.6, suggesting the utility of phenotype-based variant prioritization. Our results suggest that a combination of multiple annotation tools and appropriate evaluation can improve the diagnosis of rare diseases.
Aspartame, an artificial sweetener, is consumed by millions of people globally. There are multiple reports of aspartame and its metabolites affecting cognitive functions in animal models and humans, which include learning problems, headaches, seizures, migraines, irritable moods, anxiety, depression, and insomnia. These cognitive deficits and associated symptoms are partly attributed to dysregulated excitatory and inhibitory neurotransmitter balance due to aspartate released from aspartame, resulting in an excitotoxic effect in neurons, leading to neuronal damage. However, microglia, a central immunocompetent cell type in brain tissue and a significant player in inflammation can contribute to the impact. Microglia rapidly respond to changes in CNS homeostasis. Aspartame consumption might affect the microglia phenotype directly via methanol-induced toxic effects and indirectly via aspartic acid-mediated excitotoxicity, exacerbating symptoms of cognitive decline. Long-term oral consumption of aspartame thus might change microglia's phenotype from ramified to activated, resulting in chronic or sustained activation, releasing excess pro-inflammatory molecules. This pro-inflammatory surge might lead to the degeneration of healthy neurons and other glial cells, impairing cognition. This review will deliberate on possible links and research gaps that need to be explored concerning aspartame consumption, ecotoxicity and microglia-mediated inflammatory cognitive impairment. The study covers a comprehensive analysis of the impact of aspartame consumption on cognitive function, considering both direct and indirect effects, including the involvement of microglia-mediated neuroinflammation. We also propose a novel intervention strategy involving tryptophan supplementation to mitigate cognitive decline symptoms in individuals with prolonged aspartame consumption, providing a potential solution to address the adverse effects of aspartame on cognitive function.